nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP2B6—Thiotepa—urinary bladder cancer	0.12	0.223	CbGbCtD
Fluvoxamine—ABCB1—Mitomycin—urinary bladder cancer	0.0811	0.151	CbGbCtD
Fluvoxamine—CYP3A4—Thiotepa—urinary bladder cancer	0.0368	0.0684	CbGbCtD
Fluvoxamine—CYP2B6—Cisplatin—urinary bladder cancer	0.0331	0.0614	CbGbCtD
Fluvoxamine—CYP2E1—Etoposide—urinary bladder cancer	0.033	0.0612	CbGbCtD
Fluvoxamine—CYP3A5—Etoposide—urinary bladder cancer	0.0256	0.0476	CbGbCtD
Fluvoxamine—ABCB1—Gemcitabine—urinary bladder cancer	0.0233	0.0434	CbGbCtD
Fluvoxamine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0228	0.0424	CbGbCtD
Fluvoxamine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0222	0.0412	CbGbCtD
Fluvoxamine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0206	0.0382	CbGbCtD
Fluvoxamine—CYP1A2—Etoposide—urinary bladder cancer	0.0191	0.0354	CbGbCtD
Fluvoxamine—CYP2C9—Cisplatin—urinary bladder cancer	0.0175	0.0325	CbGbCtD
Fluvoxamine—ABCB1—Cisplatin—urinary bladder cancer	0.017	0.0315	CbGbCtD
Fluvoxamine—ABCB1—Etoposide—urinary bladder cancer	0.0167	0.0309	CbGbCtD
Fluvoxamine—ABCB1—Doxorubicin—urinary bladder cancer	0.0114	0.0211	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—urinary bladder cancer	0.011	0.0204	CbGbCtD
Fluvoxamine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0107	0.0199	CbGbCtD
Fluvoxamine—CYP3A4—Etoposide—urinary bladder cancer	0.00999	0.0185	CbGbCtD
Fluvoxamine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00681	0.0126	CbGbCtD
Fluvoxamine—CYP2C19—urine—urinary bladder cancer	0.00396	0.0878	CbGeAlD
Fluvoxamine—CYP1A2—urine—urinary bladder cancer	0.00323	0.0717	CbGeAlD
Fluvoxamine—CYP2C9—urine—urinary bladder cancer	0.00307	0.068	CbGeAlD
Fluvoxamine—CYP2E1—urine—urinary bladder cancer	0.00291	0.0645	CbGeAlD
Fluvoxamine—CYP3A4—urine—urinary bladder cancer	0.00234	0.0519	CbGeAlD
Fluvoxamine—CYP2D6—urine—urinary bladder cancer	0.0023	0.0511	CbGeAlD
Fluvoxamine—SIGMAR1—prostate gland—urinary bladder cancer	0.0017	0.0378	CbGeAlD
Fluvoxamine—SIGMAR1—seminal vesicle—urinary bladder cancer	0.00144	0.0319	CbGeAlD
Fluvoxamine—SIGMAR1—smooth muscle tissue—urinary bladder cancer	0.0012	0.0267	CbGeAlD
Fluvoxamine—SIGMAR1—urethra—urinary bladder cancer	0.00114	0.0253	CbGeAlD
Fluvoxamine—CYP3A5—prostate gland—urinary bladder cancer	0.00112	0.0248	CbGeAlD
Fluvoxamine—CYP2E1—prostate gland—urinary bladder cancer	0.00104	0.0231	CbGeAlD
Fluvoxamine—SLC6A4—female reproductive system—urinary bladder cancer	0.000935	0.0208	CbGeAlD
Fluvoxamine—CYP2E1—seminal vesicle—urinary bladder cancer	0.000882	0.0196	CbGeAlD
Fluvoxamine—CYP1A1—epithelium—urinary bladder cancer	0.000841	0.0186	CbGeAlD
Fluvoxamine—SIGMAR1—vagina—urinary bladder cancer	0.00084	0.0186	CbGeAlD
Fluvoxamine—CYP1A2—renal system—urinary bladder cancer	0.00079	0.0175	CbGeAlD
Fluvoxamine—CYP1A1—renal system—urinary bladder cancer	0.00078	0.0173	CbGeAlD
Fluvoxamine—CYP1A1—urethra—urinary bladder cancer	0.000766	0.017	CbGeAlD
Fluvoxamine—CYP3A5—renal system—urinary bladder cancer	0.000762	0.0169	CbGeAlD
Fluvoxamine—CYP2B6—renal system—urinary bladder cancer	0.000758	0.0168	CbGeAlD
Fluvoxamine—CYP2E1—renal system—urinary bladder cancer	0.000711	0.0158	CbGeAlD
Fluvoxamine—CYP2C19—vagina—urinary bladder cancer	0.000701	0.0156	CbGeAlD
Fluvoxamine—CYP2E1—urethra—urinary bladder cancer	0.000698	0.0155	CbGeAlD
Fluvoxamine—CYP1A1—female reproductive system—urinary bladder cancer	0.000624	0.0139	CbGeAlD
Fluvoxamine—CYP2B6—female reproductive system—urinary bladder cancer	0.000607	0.0135	CbGeAlD
Fluvoxamine—CYP2C9—female reproductive system—urinary bladder cancer	0.000601	0.0133	CbGeAlD
Fluvoxamine—ABCB1—prostate gland—urinary bladder cancer	0.000594	0.0132	CbGeAlD
Fluvoxamine—CYP3A4—renal system—urinary bladder cancer	0.000572	0.0127	CbGeAlD
Fluvoxamine—CYP2E1—female reproductive system—urinary bladder cancer	0.000569	0.0126	CbGeAlD
Fluvoxamine—CYP1A1—vagina—urinary bladder cancer	0.000565	0.0125	CbGeAlD
Fluvoxamine—CYP2D6—renal system—urinary bladder cancer	0.000563	0.0125	CbGeAlD
Fluvoxamine—CYP3A5—vagina—urinary bladder cancer	0.000552	0.0123	CbGeAlD
Fluvoxamine—CYP2B6—vagina—urinary bladder cancer	0.000549	0.0122	CbGeAlD
Fluvoxamine—SIGMAR1—lymph node—urinary bladder cancer	0.000543	0.0121	CbGeAlD
Fluvoxamine—ABCB1—seminal vesicle—urinary bladder cancer	0.000503	0.0112	CbGeAlD
Fluvoxamine—CYP3A4—female reproductive system—urinary bladder cancer	0.000458	0.0102	CbGeAlD
Fluvoxamine—CYP2D6—female reproductive system—urinary bladder cancer	0.000451	0.01	CbGeAlD
Fluvoxamine—ABCB1—epithelium—urinary bladder cancer	0.000437	0.00969	CbGeAlD
Fluvoxamine—ABCB1—renal system—urinary bladder cancer	0.000405	0.00899	CbGeAlD
Fluvoxamine—ABCB1—urethra—urinary bladder cancer	0.000398	0.00883	CbGeAlD
Fluvoxamine—CYP1A1—lymph node—urinary bladder cancer	0.000365	0.0081	CbGeAlD
Fluvoxamine—ABCB1—female reproductive system—urinary bladder cancer	0.000324	0.0072	CbGeAlD
Fluvoxamine—ABCB1—vagina—urinary bladder cancer	0.000293	0.00651	CbGeAlD
Fluvoxamine—ABCB1—lymph node—urinary bladder cancer	0.00019	0.00421	CbGeAlD
Fluvoxamine—Eye disorder—Methotrexate—urinary bladder cancer	0.000107	0.000363	CcSEcCtD
Fluvoxamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000107	0.000362	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—urinary bladder cancer	0.000107	0.000362	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000107	0.000361	CcSEcCtD
Fluvoxamine—Asthenia—Cisplatin—urinary bladder cancer	0.000106	0.00036	CcSEcCtD
Fluvoxamine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000106	0.00036	CcSEcCtD
Fluvoxamine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000106	0.00036	CcSEcCtD
Fluvoxamine—Sweating—Doxorubicin—urinary bladder cancer	0.000106	0.000359	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000106	0.000359	CcSEcCtD
Fluvoxamine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000106	0.000358	CcSEcCtD
Fluvoxamine—Haematuria—Doxorubicin—urinary bladder cancer	0.000105	0.000357	CcSEcCtD
Fluvoxamine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000105	0.000356	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000105	0.000354	CcSEcCtD
Fluvoxamine—Epistaxis—Doxorubicin—urinary bladder cancer	0.000104	0.000353	CcSEcCtD
Fluvoxamine—Angiopathy—Methotrexate—urinary bladder cancer	0.000104	0.000352	CcSEcCtD
Fluvoxamine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000104	0.000351	CcSEcCtD
Fluvoxamine—Dizziness—Fluorouracil—urinary bladder cancer	0.000103	0.00035	CcSEcCtD
Fluvoxamine—Visual impairment—Epirubicin—urinary bladder cancer	0.000103	0.00035	CcSEcCtD
Fluvoxamine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000103	0.000349	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—urinary bladder cancer	0.000103	0.000348	CcSEcCtD
Fluvoxamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000102	0.000344	CcSEcCtD
Fluvoxamine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000101	0.000343	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—urinary bladder cancer	0.000101	0.000343	CcSEcCtD
Fluvoxamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000101	0.000343	CcSEcCtD
Fluvoxamine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000101	0.000342	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—urinary bladder cancer	0.0001	0.00034	CcSEcCtD
Fluvoxamine—Rash—Gemcitabine—urinary bladder cancer	0.0001	0.00034	CcSEcCtD
Fluvoxamine—Dermatitis—Gemcitabine—urinary bladder cancer	0.0001	0.000339	CcSEcCtD
Fluvoxamine—Eye disorder—Epirubicin—urinary bladder cancer	0.0001	0.000339	CcSEcCtD
Fluvoxamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.0001	0.000339	CcSEcCtD
Fluvoxamine—Tinnitus—Epirubicin—urinary bladder cancer	0.0001	0.000338	CcSEcCtD
Fluvoxamine—Malnutrition—Methotrexate—urinary bladder cancer	9.98e-05	0.000338	CcSEcCtD
Fluvoxamine—Haemoglobin—Doxorubicin—urinary bladder cancer	9.97e-05	0.000338	CcSEcCtD
Fluvoxamine—Headache—Gemcitabine—urinary bladder cancer	9.97e-05	0.000338	CcSEcCtD
Fluvoxamine—Cardiac disorder—Epirubicin—urinary bladder cancer	9.95e-05	0.000337	CcSEcCtD
Fluvoxamine—Vomiting—Fluorouracil—urinary bladder cancer	9.95e-05	0.000337	CcSEcCtD
Fluvoxamine—Rhinitis—Doxorubicin—urinary bladder cancer	9.95e-05	0.000337	CcSEcCtD
Fluvoxamine—Hepatitis—Doxorubicin—urinary bladder cancer	9.92e-05	0.000336	CcSEcCtD
Fluvoxamine—Haemorrhage—Doxorubicin—urinary bladder cancer	9.92e-05	0.000336	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	9.87e-05	0.000334	CcSEcCtD
Fluvoxamine—Rash—Fluorouracil—urinary bladder cancer	9.87e-05	0.000334	CcSEcCtD
Fluvoxamine—Dermatitis—Fluorouracil—urinary bladder cancer	9.86e-05	0.000334	CcSEcCtD
Fluvoxamine—Pharyngitis—Doxorubicin—urinary bladder cancer	9.85e-05	0.000333	CcSEcCtD
Fluvoxamine—Headache—Fluorouracil—urinary bladder cancer	9.81e-05	0.000332	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	9.8e-05	0.000332	CcSEcCtD
Fluvoxamine—Oedema peripheral—Doxorubicin—urinary bladder cancer	9.78e-05	0.000331	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—urinary bladder cancer	9.77e-05	0.000331	CcSEcCtD
Fluvoxamine—Asthenia—Etoposide—urinary bladder cancer	9.75e-05	0.00033	CcSEcCtD
Fluvoxamine—Angiopathy—Epirubicin—urinary bladder cancer	9.73e-05	0.000329	CcSEcCtD
Fluvoxamine—Urethral disorder—Doxorubicin—urinary bladder cancer	9.73e-05	0.000329	CcSEcCtD
Fluvoxamine—Back pain—Methotrexate—urinary bladder cancer	9.65e-05	0.000327	CcSEcCtD
Fluvoxamine—Chills—Epirubicin—urinary bladder cancer	9.62e-05	0.000326	CcSEcCtD
Fluvoxamine—Pruritus—Etoposide—urinary bladder cancer	9.62e-05	0.000326	CcSEcCtD
Fluvoxamine—Arrhythmia—Epirubicin—urinary bladder cancer	9.58e-05	0.000324	CcSEcCtD
Fluvoxamine—Visual impairment—Doxorubicin—urinary bladder cancer	9.56e-05	0.000324	CcSEcCtD
Fluvoxamine—Alopecia—Epirubicin—urinary bladder cancer	9.48e-05	0.000321	CcSEcCtD
Fluvoxamine—Nausea—Gemcitabine—urinary bladder cancer	9.46e-05	0.00032	CcSEcCtD
Fluvoxamine—Vomiting—Cisplatin—urinary bladder cancer	9.43e-05	0.000319	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—urinary bladder cancer	9.4e-05	0.000318	CcSEcCtD
Fluvoxamine—Mental disorder—Epirubicin—urinary bladder cancer	9.4e-05	0.000318	CcSEcCtD
Fluvoxamine—Erythema multiforme—Doxorubicin—urinary bladder cancer	9.38e-05	0.000318	CcSEcCtD
Fluvoxamine—Rash—Cisplatin—urinary bladder cancer	9.36e-05	0.000317	CcSEcCtD
Fluvoxamine—Dermatitis—Cisplatin—urinary bladder cancer	9.35e-05	0.000316	CcSEcCtD
Fluvoxamine—Malnutrition—Epirubicin—urinary bladder cancer	9.34e-05	0.000316	CcSEcCtD
Fluvoxamine—Diarrhoea—Etoposide—urinary bladder cancer	9.3e-05	0.000315	CcSEcCtD
Fluvoxamine—Nausea—Fluorouracil—urinary bladder cancer	9.3e-05	0.000315	CcSEcCtD
Fluvoxamine—Eye disorder—Doxorubicin—urinary bladder cancer	9.27e-05	0.000314	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—urinary bladder cancer	9.26e-05	0.000313	CcSEcCtD
Fluvoxamine—Tinnitus—Doxorubicin—urinary bladder cancer	9.25e-05	0.000313	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—urinary bladder cancer	9.22e-05	0.000312	CcSEcCtD
Fluvoxamine—Cardiac disorder—Doxorubicin—urinary bladder cancer	9.21e-05	0.000312	CcSEcCtD
Fluvoxamine—Flatulence—Epirubicin—urinary bladder cancer	9.2e-05	0.000311	CcSEcCtD
Fluvoxamine—Tension—Epirubicin—urinary bladder cancer	9.16e-05	0.00031	CcSEcCtD
Fluvoxamine—Dysgeusia—Epirubicin—urinary bladder cancer	9.14e-05	0.000309	CcSEcCtD
Fluvoxamine—Nervousness—Epirubicin—urinary bladder cancer	9.07e-05	0.000307	CcSEcCtD
Fluvoxamine—Back pain—Epirubicin—urinary bladder cancer	9.03e-05	0.000306	CcSEcCtD
Fluvoxamine—Angiopathy—Doxorubicin—urinary bladder cancer	9e-05	0.000305	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—urinary bladder cancer	9e-05	0.000305	CcSEcCtD
Fluvoxamine—Dizziness—Etoposide—urinary bladder cancer	8.99e-05	0.000304	CcSEcCtD
Fluvoxamine—Muscle spasms—Epirubicin—urinary bladder cancer	8.98e-05	0.000304	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—urinary bladder cancer	8.96e-05	0.000303	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—urinary bladder cancer	8.93e-05	0.000302	CcSEcCtD
Fluvoxamine—Chills—Doxorubicin—urinary bladder cancer	8.9e-05	0.000301	CcSEcCtD
Fluvoxamine—Arrhythmia—Doxorubicin—urinary bladder cancer	8.86e-05	0.0003	CcSEcCtD
Fluvoxamine—Nausea—Cisplatin—urinary bladder cancer	8.81e-05	0.000298	CcSEcCtD
Fluvoxamine—Vision blurred—Epirubicin—urinary bladder cancer	8.8e-05	0.000298	CcSEcCtD
Fluvoxamine—Alopecia—Doxorubicin—urinary bladder cancer	8.77e-05	0.000297	CcSEcCtD
Fluvoxamine—Cough—Methotrexate—urinary bladder cancer	8.71e-05	0.000295	CcSEcCtD
Fluvoxamine—Mental disorder—Doxorubicin—urinary bladder cancer	8.69e-05	0.000294	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.66e-05	0.000293	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—urinary bladder cancer	8.64e-05	0.000293	CcSEcCtD
Fluvoxamine—Vomiting—Etoposide—urinary bladder cancer	8.64e-05	0.000293	CcSEcCtD
Fluvoxamine—Malnutrition—Doxorubicin—urinary bladder cancer	8.64e-05	0.000292	CcSEcCtD
Fluvoxamine—Anaemia—Epirubicin—urinary bladder cancer	8.63e-05	0.000292	CcSEcCtD
Fluvoxamine—Agitation—Epirubicin—urinary bladder cancer	8.58e-05	0.00029	CcSEcCtD
Fluvoxamine—Rash—Etoposide—urinary bladder cancer	8.57e-05	0.00029	CcSEcCtD
Fluvoxamine—Dermatitis—Etoposide—urinary bladder cancer	8.56e-05	0.00029	CcSEcCtD
Fluvoxamine—Headache—Etoposide—urinary bladder cancer	8.52e-05	0.000288	CcSEcCtD
Fluvoxamine—Flatulence—Doxorubicin—urinary bladder cancer	8.51e-05	0.000288	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—urinary bladder cancer	8.49e-05	0.000288	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—urinary bladder cancer	8.49e-05	0.000288	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—urinary bladder cancer	8.49e-05	0.000288	CcSEcCtD
Fluvoxamine—Tension—Doxorubicin—urinary bladder cancer	8.48e-05	0.000287	CcSEcCtD
Fluvoxamine—Dysgeusia—Doxorubicin—urinary bladder cancer	8.46e-05	0.000286	CcSEcCtD
Fluvoxamine—Malaise—Epirubicin—urinary bladder cancer	8.42e-05	0.000285	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—urinary bladder cancer	8.39e-05	0.000284	CcSEcCtD
Fluvoxamine—Nervousness—Doxorubicin—urinary bladder cancer	8.39e-05	0.000284	CcSEcCtD
Fluvoxamine—Vertigo—Epirubicin—urinary bladder cancer	8.39e-05	0.000284	CcSEcCtD
Fluvoxamine—Syncope—Epirubicin—urinary bladder cancer	8.37e-05	0.000283	CcSEcCtD
Fluvoxamine—Leukopenia—Epirubicin—urinary bladder cancer	8.36e-05	0.000283	CcSEcCtD
Fluvoxamine—Back pain—Doxorubicin—urinary bladder cancer	8.36e-05	0.000283	CcSEcCtD
Fluvoxamine—Muscle spasms—Doxorubicin—urinary bladder cancer	8.31e-05	0.000281	CcSEcCtD
Fluvoxamine—Palpitations—Epirubicin—urinary bladder cancer	8.25e-05	0.000279	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—urinary bladder cancer	8.21e-05	0.000278	CcSEcCtD
Fluvoxamine—Loss of consciousness—Epirubicin—urinary bladder cancer	8.21e-05	0.000278	CcSEcCtD
Fluvoxamine—Cough—Epirubicin—urinary bladder cancer	8.15e-05	0.000276	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—urinary bladder cancer	8.14e-05	0.000276	CcSEcCtD
Fluvoxamine—Vision blurred—Doxorubicin—urinary bladder cancer	8.14e-05	0.000276	CcSEcCtD
Fluvoxamine—Convulsion—Epirubicin—urinary bladder cancer	8.09e-05	0.000274	CcSEcCtD
Fluvoxamine—Infection—Methotrexate—urinary bladder cancer	8.09e-05	0.000274	CcSEcCtD
Fluvoxamine—Nausea—Etoposide—urinary bladder cancer	8.07e-05	0.000273	CcSEcCtD
Fluvoxamine—Hypertension—Epirubicin—urinary bladder cancer	8.06e-05	0.000273	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	8.02e-05	0.000271	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—urinary bladder cancer	7.98e-05	0.00027	CcSEcCtD
Fluvoxamine—Anaemia—Doxorubicin—urinary bladder cancer	7.98e-05	0.00027	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.97e-05	0.00027	CcSEcCtD
Fluvoxamine—Myalgia—Epirubicin—urinary bladder cancer	7.95e-05	0.000269	CcSEcCtD
Fluvoxamine—Arthralgia—Epirubicin—urinary bladder cancer	7.95e-05	0.000269	CcSEcCtD
Fluvoxamine—Chest pain—Epirubicin—urinary bladder cancer	7.95e-05	0.000269	CcSEcCtD
Fluvoxamine—Agitation—Doxorubicin—urinary bladder cancer	7.94e-05	0.000269	CcSEcCtD
Fluvoxamine—Anxiety—Epirubicin—urinary bladder cancer	7.92e-05	0.000268	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.87e-05	0.000266	CcSEcCtD
Fluvoxamine—Discomfort—Epirubicin—urinary bladder cancer	7.85e-05	0.000266	CcSEcCtD
Fluvoxamine—Malaise—Doxorubicin—urinary bladder cancer	7.79e-05	0.000264	CcSEcCtD
Fluvoxamine—Dry mouth—Epirubicin—urinary bladder cancer	7.77e-05	0.000263	CcSEcCtD
Fluvoxamine—Vertigo—Doxorubicin—urinary bladder cancer	7.76e-05	0.000263	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—urinary bladder cancer	7.76e-05	0.000263	CcSEcCtD
Fluvoxamine—Syncope—Doxorubicin—urinary bladder cancer	7.75e-05	0.000262	CcSEcCtD
Fluvoxamine—Leukopenia—Doxorubicin—urinary bladder cancer	7.73e-05	0.000262	CcSEcCtD
Fluvoxamine—Confusional state—Epirubicin—urinary bladder cancer	7.68e-05	0.00026	CcSEcCtD
Fluvoxamine—Palpitations—Doxorubicin—urinary bladder cancer	7.63e-05	0.000258	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.62e-05	0.000258	CcSEcCtD
Fluvoxamine—Oedema—Epirubicin—urinary bladder cancer	7.62e-05	0.000258	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—urinary bladder cancer	7.61e-05	0.000258	CcSEcCtD
Fluvoxamine—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.59e-05	0.000257	CcSEcCtD
Fluvoxamine—Infection—Epirubicin—urinary bladder cancer	7.57e-05	0.000256	CcSEcCtD
Fluvoxamine—Cough—Doxorubicin—urinary bladder cancer	7.54e-05	0.000255	CcSEcCtD
Fluvoxamine—Shock—Epirubicin—urinary bladder cancer	7.5e-05	0.000254	CcSEcCtD
Fluvoxamine—Convulsion—Doxorubicin—urinary bladder cancer	7.48e-05	0.000253	CcSEcCtD
Fluvoxamine—Nervous system disorder—Epirubicin—urinary bladder cancer	7.47e-05	0.000253	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.46e-05	0.000253	CcSEcCtD
Fluvoxamine—Hypertension—Doxorubicin—urinary bladder cancer	7.46e-05	0.000252	CcSEcCtD
Fluvoxamine—Tachycardia—Epirubicin—urinary bladder cancer	7.44e-05	0.000252	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.42e-05	0.000251	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.37e-05	0.000249	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—urinary bladder cancer	7.36e-05	0.000249	CcSEcCtD
Fluvoxamine—Arthralgia—Doxorubicin—urinary bladder cancer	7.35e-05	0.000249	CcSEcCtD
Fluvoxamine—Chest pain—Doxorubicin—urinary bladder cancer	7.35e-05	0.000249	CcSEcCtD
Fluvoxamine—Myalgia—Doxorubicin—urinary bladder cancer	7.35e-05	0.000249	CcSEcCtD
Fluvoxamine—Anxiety—Doxorubicin—urinary bladder cancer	7.33e-05	0.000248	CcSEcCtD
Fluvoxamine—Paraesthesia—Methotrexate—urinary bladder cancer	7.31e-05	0.000247	CcSEcCtD
Fluvoxamine—Discomfort—Doxorubicin—urinary bladder cancer	7.27e-05	0.000246	CcSEcCtD
Fluvoxamine—Anorexia—Epirubicin—urinary bladder cancer	7.26e-05	0.000246	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—urinary bladder cancer	7.26e-05	0.000246	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—urinary bladder cancer	7.24e-05	0.000245	CcSEcCtD
Fluvoxamine—Dry mouth—Doxorubicin—urinary bladder cancer	7.19e-05	0.000243	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—urinary bladder cancer	7.17e-05	0.000243	CcSEcCtD
Fluvoxamine—Hypotension—Epirubicin—urinary bladder cancer	7.12e-05	0.000241	CcSEcCtD
Fluvoxamine—Confusional state—Doxorubicin—urinary bladder cancer	7.11e-05	0.000241	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—urinary bladder cancer	7.08e-05	0.00024	CcSEcCtD
Fluvoxamine—Oedema—Doxorubicin—urinary bladder cancer	7.05e-05	0.000239	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.05e-05	0.000239	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.03e-05	0.000238	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—urinary bladder cancer	7.02e-05	0.000238	CcSEcCtD
Fluvoxamine—Infection—Doxorubicin—urinary bladder cancer	7e-05	0.000237	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—urinary bladder cancer	6.96e-05	0.000236	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.94e-05	0.000235	CcSEcCtD
Fluvoxamine—Shock—Doxorubicin—urinary bladder cancer	6.94e-05	0.000235	CcSEcCtD
Fluvoxamine—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.91e-05	0.000234	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.9e-05	0.000234	CcSEcCtD
Fluvoxamine—Insomnia—Epirubicin—urinary bladder cancer	6.89e-05	0.000233	CcSEcCtD
Fluvoxamine—Tachycardia—Doxorubicin—urinary bladder cancer	6.88e-05	0.000233	CcSEcCtD
Fluvoxamine—Paraesthesia—Epirubicin—urinary bladder cancer	6.84e-05	0.000232	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.82e-05	0.000231	CcSEcCtD
Fluvoxamine—Dyspnoea—Epirubicin—urinary bladder cancer	6.79e-05	0.00023	CcSEcCtD
Fluvoxamine—Somnolence—Epirubicin—urinary bladder cancer	6.77e-05	0.000229	CcSEcCtD
Fluvoxamine—Anorexia—Doxorubicin—urinary bladder cancer	6.72e-05	0.000227	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—urinary bladder cancer	6.71e-05	0.000227	CcSEcCtD
Fluvoxamine—Dyspepsia—Epirubicin—urinary bladder cancer	6.71e-05	0.000227	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.66e-05	0.000225	CcSEcCtD
Fluvoxamine—Decreased appetite—Epirubicin—urinary bladder cancer	6.62e-05	0.000224	CcSEcCtD
Fluvoxamine—Hypotension—Doxorubicin—urinary bladder cancer	6.59e-05	0.000223	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.58e-05	0.000223	CcSEcCtD
Fluvoxamine—Fatigue—Epirubicin—urinary bladder cancer	6.57e-05	0.000222	CcSEcCtD
Fluvoxamine—Pain—Epirubicin—urinary bladder cancer	6.52e-05	0.000221	CcSEcCtD
Fluvoxamine—Constipation—Epirubicin—urinary bladder cancer	6.52e-05	0.000221	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—urinary bladder cancer	6.47e-05	0.000219	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—urinary bladder cancer	6.44e-05	0.000218	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—urinary bladder cancer	6.44e-05	0.000218	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.42e-05	0.000217	CcSEcCtD
Fluvoxamine—Insomnia—Doxorubicin—urinary bladder cancer	6.38e-05	0.000216	CcSEcCtD
Fluvoxamine—Paraesthesia—Doxorubicin—urinary bladder cancer	6.33e-05	0.000214	CcSEcCtD
Fluvoxamine—Dyspnoea—Doxorubicin—urinary bladder cancer	6.29e-05	0.000213	CcSEcCtD
Fluvoxamine—Feeling abnormal—Epirubicin—urinary bladder cancer	6.28e-05	0.000213	CcSEcCtD
Fluvoxamine—Somnolence—Doxorubicin—urinary bladder cancer	6.27e-05	0.000212	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.23e-05	0.000211	CcSEcCtD
Fluvoxamine—Dyspepsia—Doxorubicin—urinary bladder cancer	6.21e-05	0.00021	CcSEcCtD
Fluvoxamine—Decreased appetite—Doxorubicin—urinary bladder cancer	6.13e-05	0.000207	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.09e-05	0.000206	CcSEcCtD
Fluvoxamine—Fatigue—Doxorubicin—urinary bladder cancer	6.08e-05	0.000206	CcSEcCtD
Fluvoxamine—Urticaria—Epirubicin—urinary bladder cancer	6.05e-05	0.000205	CcSEcCtD
Fluvoxamine—Pain—Doxorubicin—urinary bladder cancer	6.03e-05	0.000204	CcSEcCtD
Fluvoxamine—Constipation—Doxorubicin—urinary bladder cancer	6.03e-05	0.000204	CcSEcCtD
Fluvoxamine—Body temperature increased—Epirubicin—urinary bladder cancer	6.02e-05	0.000204	CcSEcCtD
Fluvoxamine—Abdominal pain—Epirubicin—urinary bladder cancer	6.02e-05	0.000204	CcSEcCtD
Fluvoxamine—Hypersensitivity—Methotrexate—urinary bladder cancer	6e-05	0.000203	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—urinary bladder cancer	5.84e-05	0.000198	CcSEcCtD
Fluvoxamine—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.81e-05	0.000197	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.77e-05	0.000195	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—urinary bladder cancer	5.76e-05	0.000195	CcSEcCtD
Fluvoxamine—Hypersensitivity—Epirubicin—urinary bladder cancer	5.61e-05	0.00019	CcSEcCtD
Fluvoxamine—Urticaria—Doxorubicin—urinary bladder cancer	5.6e-05	0.00019	CcSEcCtD
Fluvoxamine—Abdominal pain—Doxorubicin—urinary bladder cancer	5.57e-05	0.000189	CcSEcCtD
Fluvoxamine—Body temperature increased—Doxorubicin—urinary bladder cancer	5.57e-05	0.000189	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—urinary bladder cancer	5.57e-05	0.000189	CcSEcCtD
Fluvoxamine—Asthenia—Epirubicin—urinary bladder cancer	5.47e-05	0.000185	CcSEcCtD
Fluvoxamine—Pruritus—Epirubicin—urinary bladder cancer	5.39e-05	0.000182	CcSEcCtD
Fluvoxamine—Dizziness—Methotrexate—urinary bladder cancer	5.38e-05	0.000182	CcSEcCtD
Fluvoxamine—Diarrhoea—Epirubicin—urinary bladder cancer	5.21e-05	0.000176	CcSEcCtD
Fluvoxamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.19e-05	0.000176	CcSEcCtD
Fluvoxamine—Vomiting—Methotrexate—urinary bladder cancer	5.18e-05	0.000175	CcSEcCtD
Fluvoxamine—Rash—Methotrexate—urinary bladder cancer	5.13e-05	0.000174	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—urinary bladder cancer	5.13e-05	0.000174	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—urinary bladder cancer	5.1e-05	0.000173	CcSEcCtD
Fluvoxamine—Asthenia—Doxorubicin—urinary bladder cancer	5.06e-05	0.000171	CcSEcCtD
Fluvoxamine—Dizziness—Epirubicin—urinary bladder cancer	5.04e-05	0.000171	CcSEcCtD
Fluvoxamine—Pruritus—Doxorubicin—urinary bladder cancer	4.99e-05	0.000169	CcSEcCtD
Fluvoxamine—Vomiting—Epirubicin—urinary bladder cancer	4.84e-05	0.000164	CcSEcCtD
Fluvoxamine—Nausea—Methotrexate—urinary bladder cancer	4.84e-05	0.000164	CcSEcCtD
Fluvoxamine—Diarrhoea—Doxorubicin—urinary bladder cancer	4.82e-05	0.000163	CcSEcCtD
Fluvoxamine—Rash—Epirubicin—urinary bladder cancer	4.8e-05	0.000163	CcSEcCtD
Fluvoxamine—Dermatitis—Epirubicin—urinary bladder cancer	4.8e-05	0.000162	CcSEcCtD
Fluvoxamine—Headache—Epirubicin—urinary bladder cancer	4.77e-05	0.000162	CcSEcCtD
Fluvoxamine—Dizziness—Doxorubicin—urinary bladder cancer	4.66e-05	0.000158	CcSEcCtD
Fluvoxamine—Nausea—Epirubicin—urinary bladder cancer	4.53e-05	0.000153	CcSEcCtD
Fluvoxamine—Vomiting—Doxorubicin—urinary bladder cancer	4.48e-05	0.000152	CcSEcCtD
Fluvoxamine—Rash—Doxorubicin—urinary bladder cancer	4.45e-05	0.00015	CcSEcCtD
Fluvoxamine—Dermatitis—Doxorubicin—urinary bladder cancer	4.44e-05	0.00015	CcSEcCtD
Fluvoxamine—Headache—Doxorubicin—urinary bladder cancer	4.42e-05	0.00015	CcSEcCtD
Fluvoxamine—Nausea—Doxorubicin—urinary bladder cancer	4.19e-05	0.000142	CcSEcCtD
Fluvoxamine—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	2.8e-05	0.000231	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.79e-05	0.000231	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NAT2—urinary bladder cancer	2.79e-05	0.00023	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.78e-05	0.00023	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NAT2—urinary bladder cancer	2.78e-05	0.00023	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.75e-05	0.000227	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.74e-05	0.000226	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	2.73e-05	0.000226	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.71e-05	0.000224	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	2.66e-05	0.00022	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NAT2—urinary bladder cancer	2.63e-05	0.000217	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.61e-05	0.000216	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.54e-05	0.00021	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	2.52e-05	0.000208	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.49e-05	0.000206	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—NQO1—urinary bladder cancer	2.48e-05	0.000205	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—RRM2—urinary bladder cancer	2.46e-05	0.000203	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—RRM2—urinary bladder cancer	2.4e-05	0.000199	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.4e-05	0.000198	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.38e-05	0.000197	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.38e-05	0.000196	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—TYMP—urinary bladder cancer	2.38e-05	0.000196	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.36e-05	0.000195	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.36e-05	0.000195	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.32e-05	0.000192	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.32e-05	0.000191	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.28e-05	0.000189	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.28e-05	0.000188	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	2.27e-05	0.000188	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ENO2—urinary bladder cancer	2.27e-05	0.000188	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—RRM2—urinary bladder cancer	2.27e-05	0.000187	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ENO2—urinary bladder cancer	2.23e-05	0.000184	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	2.23e-05	0.000184	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.23e-05	0.000184	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.22e-05	0.000184	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.22e-05	0.000184	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	2.21e-05	0.000182	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.19e-05	0.000181	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.17e-05	0.00018	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.17e-05	0.000179	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	2.16e-05	0.000179	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.16e-05	0.000178	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.16e-05	0.000178	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.15e-05	0.000178	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.12e-05	0.000175	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.1e-05	0.000174	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	2.1e-05	0.000174	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ENO2—urinary bladder cancer	2.1e-05	0.000174	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.1e-05	0.000173	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.09e-05	0.000173	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.08e-05	0.000172	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	2.07e-05	0.000171	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	2.04e-05	0.000168	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.01e-05	0.000166	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.98e-05	0.000163	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.96e-05	0.000162	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.94e-05	0.000161	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—TYMS—urinary bladder cancer	1.92e-05	0.000159	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	1.9e-05	0.000157	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	1.9e-05	0.000157	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.87e-05	0.000155	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.86e-05	0.000154	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.86e-05	0.000153	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.85e-05	0.000153	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.83e-05	0.000152	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—NQO1—urinary bladder cancer	1.83e-05	0.000151	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.82e-05	0.00015	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.81e-05	0.00015	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NQO1—urinary bladder cancer	1.8e-05	0.000148	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.79e-05	0.000148	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.79e-05	0.000148	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.79e-05	0.000148	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.78e-05	0.000147	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.72e-05	0.000142	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.72e-05	0.000142	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.71e-05	0.000141	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.71e-05	0.000141	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NQO1—urinary bladder cancer	1.69e-05	0.00014	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.69e-05	0.00014	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.68e-05	0.000139	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.68e-05	0.000139	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.68e-05	0.000139	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.67e-05	0.000138	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.67e-05	0.000138	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.64e-05	0.000136	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.64e-05	0.000136	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.63e-05	0.000134	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.58e-05	0.000131	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.58e-05	0.000131	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.57e-05	0.000129	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.57e-05	0.000129	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.56e-05	0.000129	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.53e-05	0.000127	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.53e-05	0.000126	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.52e-05	0.000126	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.52e-05	0.000126	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	1.5e-05	0.000124	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.5e-05	0.000124	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.49e-05	0.000123	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.45e-05	0.000119	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.43e-05	0.000118	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.43e-05	0.000118	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.42e-05	0.000117	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	1.41e-05	0.000117	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.4e-05	0.000116	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.4e-05	0.000116	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—TYMS—urinary bladder cancer	1.39e-05	0.000115	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.39e-05	0.000115	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.38e-05	0.000114	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	1.38e-05	0.000114	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	1.38e-05	0.000114	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.37e-05	0.000113	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.37e-05	0.000113	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.37e-05	0.000113	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.36e-05	0.000113	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.35e-05	0.000112	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.35e-05	0.000111	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.34e-05	0.000111	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.34e-05	0.000111	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.34e-05	0.000111	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.33e-05	0.00011	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.32e-05	0.000109	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GPX1—urinary bladder cancer	1.32e-05	0.000109	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.31e-05	0.000109	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—TYMS—urinary bladder cancer	1.31e-05	0.000108	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.31e-05	0.000108	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.3e-05	0.000107	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	1.3e-05	0.000107	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	1.3e-05	0.000107	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	1.29e-05	0.000107	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.29e-05	0.000107	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.29e-05	0.000107	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.28e-05	0.000106	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.27e-05	0.000105	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.26e-05	0.000104	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GPX1—urinary bladder cancer	1.24e-05	0.000103	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.24e-05	0.000103	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.23e-05	0.000101	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	1.22e-05	0.000101	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	1.22e-05	0.000101	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.21e-05	0.0001	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.17e-05	9.69e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.16e-05	9.55e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	1.15e-05	9.48e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.13e-05	9.32e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.12e-05	9.24e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.12e-05	9.22e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.08e-05	8.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.07e-05	8.88e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.07e-05	8.85e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.07e-05	8.83e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.06e-05	8.78e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.06e-05	8.77e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.06e-05	8.77e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.05e-05	8.71e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.05e-05	8.66e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.05e-05	8.65e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.04e-05	8.56e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.04e-05	8.56e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.03e-05	8.54e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.03e-05	8.54e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.02e-05	8.42e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.02e-05	8.4e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.01e-05	8.32e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1e-05	8.28e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	9.98e-06	8.25e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.92e-06	8.2e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	9.88e-06	8.16e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PPARG—urinary bladder cancer	9.86e-06	8.15e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PPARG—urinary bladder cancer	9.84e-06	8.13e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	9.79e-06	8.09e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	9.76e-06	8.07e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	9.76e-06	8.07e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	9.74e-06	8.05e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	9.68e-06	8e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	9.68e-06	8e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	9.67e-06	7.99e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	9.47e-06	7.83e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	9.45e-06	7.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	9.38e-06	7.75e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	9.35e-06	7.73e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTEN—urinary bladder cancer	9.34e-06	7.72e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PPARG—urinary bladder cancer	9.3e-06	7.68e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	9.27e-06	7.66e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	9.18e-06	7.59e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.16e-06	7.57e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.13e-06	7.55e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	9.1e-06	7.52e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	9e-06	7.44e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	8.93e-06	7.38e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—EP300—urinary bladder cancer	8.91e-06	7.36e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.71e-06	7.2e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	8.63e-06	7.13e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	8.55e-06	7.07e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	8.37e-06	6.92e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.33e-06	6.88e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	8.27e-06	6.84e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	8.27e-06	6.84e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.92e-06	6.55e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	7.92e-06	6.55e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	7.78e-06	6.43e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	7.76e-06	6.41e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	7.74e-06	6.4e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	7.61e-06	6.29e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.42e-06	6.14e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	7.31e-06	6.04e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	7.31e-06	6.04e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	7.31e-06	6.04e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.13e-06	5.9e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	7e-06	5.78e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.95e-06	5.74e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.94e-06	5.73e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	6.91e-06	5.71e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	6.76e-06	5.59e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.75e-06	5.58e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.72e-06	5.56e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	6.66e-06	5.51e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—EP300—urinary bladder cancer	6.59e-06	5.44e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.46e-06	5.34e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—EP300—urinary bladder cancer	6.45e-06	5.33e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—EP300—urinary bladder cancer	6.44e-06	5.32e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.38e-06	5.28e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.38e-06	5.28e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTEN—urinary bladder cancer	6.38e-06	5.27e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.11e-06	5.05e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—EP300—urinary bladder cancer	6.08e-06	5.03e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6e-06	4.96e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	5.98e-06	4.95e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.93e-06	4.9e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.84e-06	4.83e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.69e-06	4.71e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.64e-06	4.66e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.5e-06	4.55e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.46e-06	4.51e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	5.22e-06	4.31e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.09e-06	4.21e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.98e-06	4.11e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—EP300—urinary bladder cancer	4.86e-06	4.02e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.8e-06	3.97e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.76e-06	3.93e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.66e-06	3.85e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.58e-06	3.78e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.57e-06	3.78e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.54e-06	3.75e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.39e-06	3.63e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.07e-06	3.36e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.88e-06	3.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.6e-06	2.97e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.14e-06	2.59e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.99e-06	2.47e-05	CbGpPWpGaD
